GEP20063861B - Injection solution comprising lhrh antagonist - Google Patents

Injection solution comprising lhrh antagonist

Info

Publication number
GEP20063861B
GEP20063861B GE5568A GEAP2002005568A GEP20063861B GE P20063861 B GEP20063861 B GE P20063861B GE 5568 A GE5568 A GE 5568A GE AP2002005568 A GEAP2002005568 A GE AP2002005568A GE P20063861 B GEP20063861 B GE P20063861B
Authority
GE
Georgia
Prior art keywords
injection solution
lhrh antagonist
lhrh
antagonist
aggregation
Prior art date
Application number
GE5568A
Inventor
Werner Sarlikiotis
Horst Bauer
Matthias Rischer
Juergen Engel
Frank Gűthlein
Stefano Dominique Di
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of GEP20063861B publication Critical patent/GEP20063861B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Abstract

1. Technical Result Prevention of LHRH antagonist aggregation in injection solution. 2. Essence The injection solution comprises an LHRH antagonist, gluconic acid, a surfactant and also a framework builder. 3. Field of Application Medicine.
GE5568A 2001-11-26 2002-11-15 Injection solution comprising lhrh antagonist GEP20063861B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10157628A DE10157628A1 (en) 2001-11-26 2001-11-26 Solution for injection of an LHRH antagonist

Publications (1)

Publication Number Publication Date
GEP20063861B true GEP20063861B (en) 2006-06-26

Family

ID=7706799

Family Applications (1)

Application Number Title Priority Date Filing Date
GE5568A GEP20063861B (en) 2001-11-26 2002-11-15 Injection solution comprising lhrh antagonist

Country Status (33)

Country Link
EP (1) EP1448221B1 (en)
JP (1) JP4343693B2 (en)
KR (1) KR100936636B1 (en)
CN (1) CN100404068C (en)
AR (1) AR037424A1 (en)
AT (1) ATE350050T1 (en)
AU (1) AU2002365504B2 (en)
BR (1) BRPI0214412B8 (en)
CO (1) CO5580793A2 (en)
CY (1) CY1106401T1 (en)
DE (2) DE10157628A1 (en)
DK (1) DK1448221T3 (en)
EA (1) EA010787B1 (en)
ES (1) ES2276970T3 (en)
GE (1) GEP20063861B (en)
HK (1) HK1073078A1 (en)
HR (1) HRP20040587B1 (en)
HU (1) HU230992B1 (en)
IL (2) IL161894A0 (en)
IS (1) IS2725B (en)
ME (1) ME00499B (en)
MX (1) MXPA04005018A (en)
NO (1) NO333364B1 (en)
NZ (1) NZ533712A (en)
PL (1) PL206199B1 (en)
PT (1) PT1448221E (en)
RS (1) RS51408B (en)
RU (1) RU2322969C2 (en)
SI (1) SI1448221T1 (en)
TW (1) TWI312283B (en)
UA (1) UA81612C2 (en)
WO (1) WO2003045419A1 (en)
ZA (1) ZA200404051B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
BRPI0710503A2 (en) 2006-04-07 2011-08-16 Merrion Res Iii Ltd use of a pharmaceutical composition, pharmaceutical composition, and oral dosage form
KR20110007242A (en) * 2008-05-07 2011-01-21 메리온 리서치 Ⅲ 리미티드 Compositions of peptides and processes of preparation thereof
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
WO2012094598A2 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
CN103690560B (en) * 2013-12-17 2016-08-17 辽宁海思科制药有限公司 A kind of Invert sugar electrolyte injection pharmaceutical composition and preparation method thereof
CN107205948B (en) 2015-01-29 2021-12-14 诺和诺德股份有限公司 Tablets comprising a GLP-1 agonist and an enteric coating
RU2614234C2 (en) * 2015-03-31 2017-03-23 Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН) PHARMACEUTICAL COMPOSITION BASED ON 3-(4-METHYLIMIDAZOLE-1-YL)IMIDAZO[1,2-b][1,2,4,5]TETRAZINE AS ANTI-TUMOR AGENT
CN110248679A (en) * 2017-01-30 2019-09-17 安迪威有限公司 Composition comprising at least one GnRH antagonist
PT3811927T (en) 2019-10-24 2021-12-14 Sun Pharmaceutical Ind Ltd A stable parenteral dosage form of cetrorelix acetate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US5300492A (en) * 1988-02-10 1994-04-05 Tap Pharmaceuticals LHRH analogs
US5140009A (en) * 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
RU2255759C2 (en) * 1999-09-23 2005-07-10 Центарис Гмбх Method for therapeutic treatment of extrauterine proliferation of endometrial tissue chronic pain in pelvis region caused by thereof and fallopian tubes impenetrability
DE10024451A1 (en) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmaceutical dosage form for peptides, process for their preparation and use

Also Published As

Publication number Publication date
JP2005510544A (en) 2005-04-21
ATE350050T1 (en) 2007-01-15
RS51408B (en) 2011-02-28
NZ533712A (en) 2006-01-27
SI1448221T1 (en) 2007-06-30
KR20040058312A (en) 2004-07-03
CN1592630A (en) 2005-03-09
KR100936636B1 (en) 2010-01-14
ES2276970T3 (en) 2007-07-01
CO5580793A2 (en) 2005-11-30
IL161894A0 (en) 2005-11-20
TWI312283B (en) 2009-07-21
CY1106401T1 (en) 2011-10-12
TW200300352A (en) 2003-06-01
WO2003045419A1 (en) 2003-06-05
RU2322969C2 (en) 2008-04-27
AU2002365504A1 (en) 2003-06-10
CN100404068C (en) 2008-07-23
NO20042449L (en) 2004-06-11
EP1448221A1 (en) 2004-08-25
EA010787B1 (en) 2008-10-30
IL161894A (en) 2014-05-28
EA200400742A1 (en) 2004-12-30
HRP20040587B1 (en) 2008-01-31
IS7251A (en) 2004-05-06
HUP0401986A3 (en) 2012-09-28
BRPI0214412B1 (en) 2016-01-05
EP1448221B1 (en) 2007-01-03
AU2002365504B2 (en) 2007-06-28
ME00499B (en) 2011-10-10
NO333364B1 (en) 2013-05-13
BR0214412A (en) 2004-09-14
MXPA04005018A (en) 2004-08-11
PT1448221E (en) 2007-03-30
HK1073078A1 (en) 2005-09-23
RS44904A (en) 2006-10-27
DE50209193D1 (en) 2007-02-15
UA81612C2 (en) 2008-01-25
ZA200404051B (en) 2005-05-25
PL206199B1 (en) 2010-07-30
PL369548A1 (en) 2005-05-02
HRP20040587A2 (en) 2004-10-31
HU230992B1 (en) 2019-08-28
RU2004119821A (en) 2005-04-20
JP4343693B2 (en) 2009-10-14
DK1448221T3 (en) 2007-03-19
BRPI0214412B8 (en) 2021-05-25
IS2725B (en) 2011-03-15
AR037424A1 (en) 2004-11-10
DE10157628A1 (en) 2003-06-12
HUP0401986A2 (en) 2005-01-28

Similar Documents

Publication Publication Date Title
DK0703786T3 (en) Use of nona- and decapeptides for the manufacture of a medicament for the treatment of AIDS
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
WO2002051470A3 (en) Injection systems
MY129356A (en) Electrospun pharmaceutical compositions
AU2002338494A1 (en) Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof
GEP20053602B (en) Aripiprazole for Oral Administration
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
HK1054918A1 (en) Compounds and compositions for delivering active agents
WO2003045878A3 (en) 2,w-diaminocarboxylic acid compounds
FI20011851A (en) Fluoxetine or its acid addition salt dispersible tablet
ATE514418T1 (en) RAPIDLY DISRUPTING SOLID DOSAGE FORMS WITH NON-FRUABLE CONSISTENCY AND PULLULAN
AU3058902A (en) Fast dissolving tablet
IT1304152B1 (en) COMPOSITIONS INCLUDING A PEPTIDE AND POLYLACTIC-GLYCOLIC ACID FOR THE PREPARATION OF SUBCUTANEOUS IMPLANTS HAVING A PROLONGED
AP2002002558A0 (en) Pharmaceutical compositions containing polymer and drug assemblies.
GEP20063861B (en) Injection solution comprising lhrh antagonist
MXPA02012937A (en) Combinations of active ingredients, which exhibit insecticidal and acaricidal properties.
MXPA03007857A (en) Compounds and compositions for delivering active agents.
MY127908A (en) Improved pharmaceutical formulations.
EP1453525A4 (en) Selective targeting of apoptotic cells
GB0004827D0 (en) Compositions
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
WO2002000208A3 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined with specific pharmaceutical active agents
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
MXPA02008870A (en) Novel lhrh antagonists, production and use thereof as medicament.
NZ528544A (en) Formulations comprising entrapped active ingredients and uses thereof